#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Academic editor : Alejandro Sosnik
1-1	0-8	Academic	person[1]	new[1]	_	_
1-2	9-15	editor	person[1]	new[1]	_	_
1-3	16-17	:	_	_	_	_
1-4	18-27	Alejandro	person[2]	new[2]	_	_
1-5	28-34	Sosnik	person[2]	new[2]	_	_

#Text=1. Introduction
2-1	35-37	1.	_	_	_	_
2-2	38-50	Introduction	abstract	new	_	_

#Text=Drug-delivery systems are difficult to design as there exist various mechanisms that are involved in the release processes of drug .
3-1	51-64	Drug-delivery	abstract[4]	new[4]	coref	5-28[27_4]
3-2	65-72	systems	abstract[4]	new[4]	_	_
3-3	73-76	are	_	_	_	_
3-4	77-86	difficult	_	_	_	_
3-5	87-89	to	_	_	_	_
3-6	90-96	design	abstract	new	coref|none	26-3[194_0]|3-6[0_194]
3-7	97-99	as	_	_	_	_
3-8	100-105	there	_	_	_	_
3-9	106-111	exist	_	_	_	_
3-10	112-119	various	abstract[5]	new[5]	_	_
3-11	120-130	mechanisms	abstract[5]	new[5]	_	_
3-12	131-135	that	abstract[5]	new[5]	_	_
3-13	136-139	are	abstract[5]	new[5]	_	_
3-14	140-148	involved	abstract[5]	new[5]	_	_
3-15	149-151	in	abstract[5]	new[5]	_	_
3-16	152-155	the	abstract[5]|abstract[7]	new[5]|new[7]	_	_
3-17	156-163	release	abstract[5]|event|abstract[7]	new[5]|new|new[7]	_	_
3-18	164-173	processes	abstract[5]|abstract[7]	new[5]|new[7]	_	_
3-19	174-176	of	abstract[5]|abstract[7]	new[5]|new[7]	_	_
3-20	177-181	drug	abstract[5]|abstract[7]|substance	new[5]|new[7]|new	coref	4-8
3-21	182-183	.	_	_	_	_

#Text=Various factors need to be considered for drug delivery , such as the degree of absorption or the diffusion limitations of the drug in the medium .
4-1	184-191	Various	abstract[9]	new[9]	coref	16-6[104_9]
4-2	192-199	factors	abstract[9]	new[9]	_	_
4-3	200-204	need	_	_	_	_
4-4	205-207	to	_	_	_	_
4-5	208-210	be	_	_	_	_
4-6	211-221	considered	_	_	_	_
4-7	222-225	for	_	_	_	_
4-8	226-230	drug	substance|event[11]	giv|new[11]	coref|coref	4-22[16_0]|5-12[23_11]
4-9	231-239	delivery	event[11]	new[11]	_	_
4-10	240-241	,	event[11]	new[11]	_	_
4-11	242-246	such	event[11]	new[11]	_	_
4-12	247-249	as	event[11]	new[11]	_	_
4-13	250-253	the	event[11]|abstract[12]	new[11]|new[12]	_	_
4-14	254-260	degree	event[11]|abstract[12]	new[11]|new[12]	_	_
4-15	261-263	of	event[11]|abstract[12]	new[11]|new[12]	_	_
4-16	264-274	absorption	event[11]|abstract[12]|event	new[11]|new[12]|new	_	_
4-17	275-277	or	event[11]	new[11]	_	_
4-18	278-281	the	event[11]|abstract[15]	new[11]|new[15]	_	_
4-19	282-291	diffusion	event[11]|abstract|abstract[15]	new[11]|new|new[15]	coref	16-2
4-20	292-303	limitations	event[11]|abstract[15]	new[11]|new[15]	_	_
4-21	304-306	of	event[11]|abstract[15]	new[11]|new[15]	_	_
4-22	307-310	the	event[11]|abstract[15]|substance[16]	new[11]|new[15]|giv[16]	coref	5-12[0_16]
4-23	311-315	drug	event[11]|abstract[15]|substance[16]	new[11]|new[15]|giv[16]	_	_
4-24	316-318	in	event[11]|abstract[15]	new[11]|new[15]	_	_
4-25	319-322	the	event[11]|abstract[15]|place[17]	new[11]|new[15]|new[17]	_	_
4-26	323-329	medium	event[11]|abstract[15]|place[17]	new[11]|new[15]|new[17]	_	_
4-27	330-331	.	_	_	_	_

#Text=In recent years , the use of porous silica materials in drug delivery has attracted a lot of interest due to its potential for the development of systems that are site-specific and that offer time-dependent controlled delivery .
5-1	332-334	In	_	_	_	_
5-2	335-341	recent	time[18]	new[18]	_	_
5-3	342-347	years	time[18]	new[18]	_	_
5-4	348-349	,	_	_	_	_
5-5	350-353	the	abstract[19]	new[19]	ana	5-22[0_19]
5-6	354-357	use	abstract[19]	new[19]	_	_
5-7	358-360	of	abstract[19]	new[19]	_	_
5-8	361-367	porous	abstract[19]|substance[21]	new[19]|new[21]	ana	6-4[0_21]
5-9	368-374	silica	abstract[19]|substance|substance[21]	new[19]|new|new[21]	coref	6-8
5-10	375-384	materials	abstract[19]|substance[21]	new[19]|new[21]	_	_
5-11	385-387	in	abstract[19]	new[19]	_	_
5-12	388-392	drug	abstract[19]|substance|event[23]	new[19]|giv|giv[23]	coref|coref	5-35[28_23]|7-45
5-13	393-401	delivery	abstract[19]|event[23]	new[19]|giv[23]	_	_
5-14	402-405	has	_	_	_	_
5-15	406-415	attracted	_	_	_	_
5-16	416-417	a	_	_	_	_
5-17	418-421	lot	_	_	_	_
5-18	422-424	of	_	_	_	_
5-19	425-433	interest	_	_	_	_
5-20	434-437	due	_	_	_	_
5-21	438-440	to	_	_	_	_
5-22	441-444	its	abstract|abstract[25]	giv|new[25]	_	_
5-23	445-454	potential	abstract[25]	new[25]	_	_
5-24	455-458	for	abstract[25]	new[25]	_	_
5-25	459-462	the	abstract[25]|event[26]	new[25]|new[26]	_	_
5-26	463-474	development	abstract[25]|event[26]	new[25]|new[26]	_	_
5-27	475-477	of	abstract[25]|event[26]	new[25]|new[26]	_	_
5-28	478-485	systems	abstract[25]|event[26]|abstract[27]	new[25]|new[26]|giv[27]	_	_
5-29	486-490	that	abstract[25]|event[26]|abstract[27]	new[25]|new[26]|giv[27]	_	_
5-30	491-494	are	abstract[25]|event[26]|abstract[27]	new[25]|new[26]|giv[27]	_	_
5-31	495-508	site-specific	abstract[25]|event[26]|abstract[27]	new[25]|new[26]|giv[27]	_	_
5-32	509-512	and	abstract[25]|event[26]|abstract[27]	new[25]|new[26]|giv[27]	_	_
5-33	513-517	that	abstract[25]|event[26]|abstract[27]	new[25]|new[26]|giv[27]	_	_
5-34	518-523	offer	abstract[25]|event[26]|abstract[27]	new[25]|new[26]|giv[27]	_	_
5-35	524-538	time-dependent	abstract[25]|event[26]|abstract[27]|event[28]	new[25]|new[26]|giv[27]|giv[28]	_	_
5-36	539-549	controlled	abstract[25]|event[26]|abstract[27]|event[28]	new[25]|new[26]|giv[27]|giv[28]	_	_
5-37	550-558	delivery	abstract[25]|event[26]|abstract[27]|event[28]	new[25]|new[26]|giv[27]|giv[28]	_	_
5-38	559-560	.	_	_	_	_

#Text=Given in particular their non-toxic properties , silica aerogels are a special kind of porous silica materials consisting of highly mesoporous nanostructures .
6-1	561-566	Given	_	_	_	_
6-2	567-569	in	_	_	_	_
6-3	570-580	particular	_	_	_	_
6-4	581-586	their	substance|abstract[30]	giv|new[30]	coref|coref	6-13[34_0]|7-8[38_30]
6-5	587-596	non-toxic	abstract[30]	new[30]	_	_
6-6	597-607	properties	abstract[30]	new[30]	_	_
6-7	608-609	,	_	_	_	_
6-8	610-616	silica	substance|substance[32]	giv|new[32]	coref|coref	6-16|7-5[37_32]
6-9	617-625	aerogels	substance[32]	new[32]	_	_
6-10	626-629	are	_	_	_	_
6-11	630-631	a	_	_	_	_
6-12	632-639	special	_	_	_	_
6-13	640-644	kind	substance[34]	giv[34]	_	_
6-14	645-647	of	substance[34]	giv[34]	_	_
6-15	648-654	porous	substance[34]	giv[34]	_	_
6-16	655-661	silica	substance|substance[34]	giv|giv[34]	coref	8-4
6-17	662-671	materials	substance[34]	giv[34]	_	_
6-18	672-682	consisting	substance[34]	giv[34]	_	_
6-19	683-685	of	substance[34]	giv[34]	_	_
6-20	686-692	highly	substance[34]|object[35]	giv[34]|new[35]	_	_
6-21	693-703	mesoporous	substance[34]|object[35]	giv[34]|new[35]	_	_
6-22	704-718	nanostructures	substance[34]|object[35]	giv[34]|new[35]	_	_
6-23	719-720	.	_	_	_	_

#Text=The porous structure make the aerogels have many special properties , such as low density ( 1000 kg/m3 to about 1 kg/m3 ) , high porosity ( ~99 % ) and inner surface area ( 1000 m2/g ) , which is necessary for efficient drug loading .
7-1	721-724	The	abstract[36]	new[36]	_	_
7-2	725-731	porous	abstract[36]	new[36]	_	_
7-3	732-741	structure	abstract[36]	new[36]	_	_
7-4	742-746	make	_	_	_	_
7-5	747-750	the	substance[37]	giv[37]	coref	8-4[50_37]
7-6	751-759	aerogels	substance[37]	giv[37]	_	_
7-7	760-764	have	_	_	_	_
7-8	765-769	many	abstract[38]	giv[38]	_	_
7-9	770-777	special	abstract[38]	giv[38]	_	_
7-10	778-788	properties	abstract[38]	giv[38]	_	_
7-11	789-790	,	abstract[38]	giv[38]	_	_
7-12	791-795	such	abstract[38]	giv[38]	_	_
7-13	796-798	as	abstract[38]	giv[38]	_	_
7-14	799-802	low	abstract[38]|abstract[39]	giv[38]|new[39]	appos	7-17[40_39]
7-15	803-810	density	abstract[38]|abstract[39]	giv[38]|new[39]	_	_
7-16	811-812	(	_	_	_	_
7-17	813-817	1000	abstract[40]	giv[40]	_	_
7-18	818-823	kg/m3	abstract[40]	giv[40]	_	_
7-19	824-826	to	abstract[40]	giv[40]	_	_
7-20	827-832	about	abstract[40]|abstract[41]	giv[40]|new[41]	_	_
7-21	833-834	1	abstract[40]|abstract[41]	giv[40]|new[41]	_	_
7-22	835-840	kg/m3	abstract[40]|abstract[41]	giv[40]|new[41]	_	_
7-23	841-842	)	_	_	_	_
7-24	843-844	,	_	_	_	_
7-25	845-849	high	substance[42]	new[42]	_	_
7-26	850-858	porosity	substance[42]	new[42]	_	_
7-27	859-860	(	_	_	_	_
7-28	861-864	~99	abstract[43]	new[43]	_	_
7-29	865-866	%	abstract[43]	new[43]	_	_
7-30	867-868	)	_	_	_	_
7-31	869-872	and	_	_	_	_
7-32	873-878	inner	abstract[45]	new[45]	appos	7-36[46_45]
7-33	879-886	surface	place|abstract[45]	new|new[45]	coref	8-13
7-34	887-891	area	abstract[45]	new[45]	_	_
7-35	892-893	(	_	_	_	_
7-36	894-898	1000	abstract[46]	giv[46]	ana	9-21[0_46]
7-37	899-903	m2/g	abstract[46]	giv[46]	_	_
7-38	904-905	)	_	_	_	_
7-39	906-907	,	_	_	_	_
7-40	908-913	which	_	_	_	_
7-41	914-916	is	_	_	_	_
7-42	917-926	necessary	_	_	_	_
7-43	927-930	for	_	_	_	_
7-44	931-940	efficient	event[48]	new[48]	coref	18-9[0_48]
7-45	941-945	drug	substance|event[48]	giv|new[48]	coref	8-19[54_0]
7-46	946-953	loading	event[48]	new[48]	_	_
7-47	954-955	.	_	_	_	_

#Text=In addition , silica aerogels can be grafted with various groups by surface modification , which could deliver the drug to targeted regions .
8-1	956-958	In	_	_	_	_
8-2	959-967	addition	_	_	_	_
8-3	968-969	,	_	_	_	_
8-4	970-976	silica	substance|substance[50]	giv|giv[50]	coref|coref	12-5|13-5[0_50]
8-5	977-985	aerogels	substance[50]	giv[50]	_	_
8-6	986-989	can	_	_	_	_
8-7	990-992	be	_	_	_	_
8-8	993-1000	grafted	_	_	_	_
8-9	1001-1005	with	_	_	_	_
8-10	1006-1013	various	person[51]	new[51]	_	_
8-11	1014-1020	groups	person[51]	new[51]	_	_
8-12	1021-1023	by	_	_	_	_
8-13	1024-1031	surface	place|event[53]	giv|new[53]	_	_
8-14	1032-1044	modification	event[53]	new[53]	_	_
8-15	1045-1046	,	event[53]	new[53]	_	_
8-16	1047-1052	which	event[53]	new[53]	_	_
8-17	1053-1058	could	event[53]	new[53]	_	_
8-18	1059-1066	deliver	event[53]	new[53]	_	_
8-19	1067-1070	the	event[53]|substance[54]	new[53]|giv[54]	coref	12-15[80_54]
8-20	1071-1075	drug	event[53]|substance[54]	new[53]|giv[54]	_	_
8-21	1076-1078	to	event[53]	new[53]	_	_
8-22	1079-1087	targeted	event[53]|place[55]	new[53]|new[55]	_	_
8-23	1088-1095	regions	event[53]|place[55]	new[53]|new[55]	_	_
8-24	1096-1097	.	_	_	_	_

#Text=Trans-resveratrol ( RSV ) , whose full name is non-flavonoid phytoalexin trans-resveratrol , has many biological functions by virtue of its antibacterial , anti-inflammatory , anticancer , anti-thrombosis , anti-hyperlipidemia and anti-lipid peroxidation characteristics .
9-1	1098-1115	Trans-resveratrol	person	new	_	_
9-2	1116-1117	(	_	_	_	_
9-3	1118-1121	RSV	abstract	new	coref	12-8
9-4	1122-1123	)	_	_	_	_
9-5	1124-1125	,	_	_	_	_
9-6	1126-1131	whose	abstract[58]|abstract[60]	new[58]|new[60]	coref	28-8[0_60]
9-7	1132-1136	full	abstract[58]|abstract[60]	new[58]|new[60]	_	_
9-8	1137-1141	name	abstract[58]|abstract[60]	new[58]|new[60]	_	_
9-9	1142-1144	is	abstract[60]	new[60]	_	_
9-10	1145-1158	non-flavonoid	abstract[60]	new[60]	_	_
9-11	1159-1170	phytoalexin	abstract|abstract[60]	new|new[60]	_	_
9-12	1171-1188	trans-resveratrol	abstract[60]	new[60]	_	_
9-13	1189-1190	,	_	_	_	_
9-14	1191-1194	has	_	_	_	_
9-15	1195-1199	many	abstract[61]	new[61]	coref	10-1[66_61]
9-16	1200-1210	biological	abstract[61]	new[61]	_	_
9-17	1211-1220	functions	abstract[61]	new[61]	_	_
9-18	1221-1223	by	_	_	_	_
9-19	1224-1230	virtue	abstract[62]	new[62]	_	_
9-20	1231-1233	of	abstract[62]	new[62]	_	_
9-21	1234-1237	its	abstract[62]|abstract|abstract[65]	new[62]|giv|new[65]	_	_
9-22	1238-1251	antibacterial	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-23	1252-1253	,	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-24	1254-1271	anti-inflammatory	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-25	1272-1273	,	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-26	1274-1284	anticancer	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-27	1285-1286	,	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-28	1287-1302	anti-thrombosis	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-29	1303-1304	,	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-30	1305-1324	anti-hyperlipidemia	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-31	1325-1328	and	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-32	1329-1339	anti-lipid	abstract[62]|event[64]|abstract[65]	new[62]|new[64]|new[65]	_	_
9-33	1340-1352	peroxidation	abstract[62]|event[64]|abstract[65]	new[62]|new[64]|new[65]	_	_
9-34	1353-1368	characteristics	abstract[62]|abstract[65]	new[62]|new[65]	_	_
9-35	1369-1370	.	_	_	_	_

#Text=These functions determined
10-1	1371-1376	These	abstract[66]	giv[66]	_	_
10-2	1377-1386	functions	abstract[66]	giv[66]	_	_
10-3	1387-1397	determined	_	_	_	_

#Text=resveratrol has many supplementations in treatment of cancer , diabetes , skin disorders and so on .
11-1	1398-1409	resveratrol	substance	new	_	_
11-2	1410-1413	has	_	_	_	_
11-3	1414-1418	many	substance[68]	new[68]	_	_
11-4	1419-1435	supplementations	substance[68]	new[68]	_	_
11-5	1436-1438	in	substance[68]	new[68]	_	_
11-6	1439-1448	treatment	substance[68]|abstract[69]	new[68]|new[69]	_	_
11-7	1449-1451	of	substance[68]|abstract[69]	new[68]|new[69]	_	_
11-8	1452-1458	cancer	substance[68]|abstract[69]|abstract	new[68]|new[69]|new	_	_
11-9	1459-1460	,	substance[68]|abstract[69]	new[68]|new[69]	_	_
11-10	1461-1469	diabetes	substance[68]|abstract[69]|abstract	new[68]|new[69]|new	_	_
11-11	1470-1471	,	substance[68]|abstract[69]	new[68]|new[69]	_	_
11-12	1472-1476	skin	substance[68]|abstract[69]|object|abstract[73]	new[68]|new[69]|new|new[73]	_	_
11-13	1477-1486	disorders	substance[68]|abstract[69]|abstract[73]	new[68]|new[69]|new[73]	_	_
11-14	1487-1490	and	substance[68]|abstract[69]	new[68]|new[69]	_	_
11-15	1491-1493	so	substance[68]|abstract[69]	new[68]|new[69]	_	_
11-16	1494-1496	on	substance[68]|abstract[69]	new[68]|new[69]	_	_
11-17	1497-1498	.	_	_	_	_

#Text=In this paper , silica aerogel and RSV was chosen as a carrier and a model drug , respectively .
12-1	1499-1501	In	_	_	_	_
12-2	1502-1506	this	abstract[74]	new[74]	coref	22-2[151_74]
12-3	1507-1512	paper	abstract[74]	new[74]	_	_
12-4	1513-1514	,	_	_	_	_
12-5	1515-1521	silica	substance|substance[76]|abstract[77]	giv|new[76]|new[77]	coref|coref|coref	22-6|22-5[153_76]|24-12[171_77]
12-6	1522-1529	aerogel	substance[76]|abstract[77]	new[76]|new[77]	_	_
12-7	1530-1533	and	abstract[77]	new[77]	_	_
12-8	1534-1537	RSV	abstract[77]|abstract	new[77]|giv	coref	15-12[97_0]
12-9	1538-1541	was	_	_	_	_
12-10	1542-1548	chosen	_	_	_	_
12-11	1549-1551	as	_	_	_	_
12-12	1552-1553	a	organization[79]	new[79]	coref	18-21[126_79]
12-13	1554-1561	carrier	organization[79]	new[79]	_	_
12-14	1562-1565	and	_	_	_	_
12-15	1566-1567	a	substance[80]	giv[80]	coref	13-18[85_80]
12-16	1568-1573	model	substance[80]	giv[80]	_	_
12-17	1574-1578	drug	substance[80]	giv[80]	_	_
12-18	1579-1580	,	_	_	_	_
12-19	1581-1593	respectively	_	_	_	_
12-20	1594-1595	.	_	_	_	_

#Text=Drug-delivery vehicles based on aerogels can be prepared by different methods , such as the addition of the drug during the conventional sol – gel process or during the post treatment of the synthesized aerogels .
13-1	1596-1609	Drug-delivery	object[81]	new[81]	_	_
13-2	1610-1618	vehicles	object[81]	new[81]	_	_
13-3	1619-1624	based	object[81]	new[81]	_	_
13-4	1625-1627	on	object[81]	new[81]	_	_
13-5	1628-1636	aerogels	object[81]|substance	new[81]|giv	coref	13-33[90_0]
13-6	1637-1640	can	_	_	_	_
13-7	1641-1643	be	_	_	_	_
13-8	1644-1652	prepared	_	_	_	_
13-9	1653-1655	by	_	_	_	_
13-10	1656-1665	different	abstract[83]	new[83]	_	_
13-11	1666-1673	methods	abstract[83]	new[83]	_	_
13-12	1674-1675	,	abstract[83]	new[83]	_	_
13-13	1676-1680	such	abstract[83]	new[83]	_	_
13-14	1681-1683	as	abstract[83]	new[83]	_	_
13-15	1684-1687	the	abstract[83]|event[84]	new[83]|new[84]	_	_
13-16	1688-1696	addition	abstract[83]|event[84]	new[83]|new[84]	_	_
13-17	1697-1699	of	abstract[83]|event[84]	new[83]|new[84]	_	_
13-18	1700-1703	the	abstract[83]|event[84]|substance[85]	new[83]|new[84]|giv[85]	coref	14-3[92_85]
13-19	1704-1708	drug	abstract[83]|event[84]|substance[85]	new[83]|new[84]|giv[85]	_	_
13-20	1709-1715	during	abstract[83]|event[84]	new[83]|new[84]	_	_
13-21	1716-1719	the	abstract[83]|event[84]|abstract[88]	new[83]|new[84]|new[88]	coref	14-6[93_88]
13-22	1720-1732	conventional	abstract[83]|event[84]|abstract[88]	new[83]|new[84]|new[88]	_	_
13-23	1733-1736	sol	abstract[83]|event[84]|substance[86]|abstract[88]	new[83]|new[84]|new[86]|new[88]	_	_
13-24	1737-1738	–	abstract[83]|event[84]|substance[86]|abstract[88]	new[83]|new[84]|new[86]|new[88]	_	_
13-25	1739-1742	gel	abstract[83]|event[84]|substance[86]|substance|abstract[88]	new[83]|new[84]|new[86]|new|new[88]	_	_
13-26	1743-1750	process	abstract[83]|event[84]|abstract[88]	new[83]|new[84]|new[88]	_	_
13-27	1751-1753	or	_	_	_	_
13-28	1754-1760	during	_	_	_	_
13-29	1761-1764	the	event[89]	new[89]	_	_
13-30	1765-1769	post	event[89]	new[89]	_	_
13-31	1770-1779	treatment	event[89]	new[89]	_	_
13-32	1780-1782	of	event[89]	new[89]	_	_
13-33	1783-1786	the	event[89]|substance[90]	new[89]|giv[90]	_	_
13-34	1787-1798	synthesized	event[89]|substance[90]	new[89]|giv[90]	_	_
13-35	1799-1807	aerogels	event[89]|substance[90]	new[89]|giv[90]	_	_
13-36	1808-1809	.	_	_	_	_

#Text=We added the drug during the aging process in this work .
14-1	1810-1812	We	person	acc	ana	20-15
14-2	1813-1818	added	_	_	_	_
14-3	1819-1822	the	substance[92]	giv[92]	coref	15-17[98_92]
14-4	1823-1827	drug	substance[92]	giv[92]	_	_
14-5	1828-1834	during	_	_	_	_
14-6	1835-1838	the	abstract[93]	giv[93]	coref	20-10[135_93]
14-7	1839-1844	aging	abstract[93]	giv[93]	_	_
14-8	1845-1852	process	abstract[93]	giv[93]	_	_
14-9	1853-1855	in	_	_	_	_
14-10	1856-1860	this	abstract[94]	new[94]	coref	21-3[140_94]
14-11	1861-1865	work	abstract[94]	new[94]	_	_
14-12	1866-1867	.	_	_	_	_

#Text=The alcogel was brought into contactwith an aging solution which contains the RSV , and then the drug diffused into the alcogel pores from the aging solution .
15-1	1868-1871	The	substance[95]	new[95]	coref	15-22[0_95]
15-2	1872-1879	alcogel	substance[95]	new[95]	_	_
15-3	1880-1883	was	_	_	_	_
15-4	1884-1891	brought	_	_	_	_
15-5	1892-1896	into	_	_	_	_
15-6	1897-1908	contactwith	_	_	_	_
15-7	1909-1911	an	substance[96]	new[96]	coref	15-25[101_96]
15-8	1912-1917	aging	substance[96]	new[96]	_	_
15-9	1918-1926	solution	substance[96]	new[96]	_	_
15-10	1927-1932	which	substance[96]	new[96]	_	_
15-11	1933-1941	contains	substance[96]	new[96]	_	_
15-12	1942-1945	the	substance[96]|abstract[97]	new[96]|giv[97]	coref	23-13[161_97]
15-13	1946-1949	RSV	substance[96]|abstract[97]	new[96]|giv[97]	_	_
15-14	1950-1951	,	_	_	_	_
15-15	1952-1955	and	_	_	_	_
15-16	1956-1960	then	_	_	_	_
15-17	1961-1964	the	substance[98]	giv[98]	coref	17-14[114_98]
15-18	1965-1969	drug	substance[98]	giv[98]	_	_
15-19	1970-1978	diffused	_	_	_	_
15-20	1979-1983	into	_	_	_	_
15-21	1984-1987	the	object[100]	new[100]	coref	16-17[0_100]
15-22	1988-1995	alcogel	substance|object[100]	giv|new[100]	coref	17-22[116_0]
15-23	1996-2001	pores	object[100]	new[100]	_	_
15-24	2002-2006	from	_	_	_	_
15-25	2007-2010	the	substance[101]	giv[101]	coref	16-24[110_101]
15-26	2011-2016	aging	substance[101]	giv[101]	_	_
15-27	2017-2025	solution	substance[101]	giv[101]	_	_
15-28	2026-2027	.	_	_	_	_

#Text=The diffusion rate depends on many factors , such as the size of the molecules and pores , and the initial concentration of the aging solution .
16-1	2028-2031	The	abstract[103]	new[103]	_	_
16-2	2032-2041	diffusion	abstract|abstract[103]	giv|new[103]	coref	20-3
16-3	2042-2046	rate	abstract[103]	new[103]	_	_
16-4	2047-2054	depends	_	_	_	_
16-5	2055-2057	on	_	_	_	_
16-6	2058-2062	many	abstract[104]	giv[104]	_	_
16-7	2063-2070	factors	abstract[104]	giv[104]	_	_
16-8	2071-2072	,	abstract[104]	giv[104]	_	_
16-9	2073-2077	such	abstract[104]	giv[104]	_	_
16-10	2078-2080	as	abstract[104]	giv[104]	_	_
16-11	2081-2084	the	abstract[104]|abstract[105]	giv[104]|new[105]	coref	35-3[245_105]
16-12	2085-2089	size	abstract[104]|abstract[105]	giv[104]|new[105]	_	_
16-13	2090-2092	of	abstract[104]|abstract[105]	giv[104]|new[105]	_	_
16-14	2093-2096	the	abstract[104]|abstract[105]|object[106]	giv[104]|new[105]|new[106]	_	_
16-15	2097-2106	molecules	abstract[104]|abstract[105]|object[106]	giv[104]|new[105]|new[106]	_	_
16-16	2107-2110	and	abstract[104]|abstract[105]	giv[104]|new[105]	_	_
16-17	2111-2116	pores	abstract[104]|abstract[105]|object	giv[104]|new[105]|giv	_	_
16-18	2117-2118	,	abstract[104]	giv[104]	_	_
16-19	2119-2122	and	abstract[104]	giv[104]	_	_
16-20	2123-2126	the	abstract[104]|substance[108]	giv[104]|new[108]	ana	17-1[0_108]
16-21	2127-2134	initial	abstract[104]|substance[108]	giv[104]|new[108]	_	_
16-22	2135-2148	concentration	abstract[104]|substance[108]	giv[104]|new[108]	_	_
16-23	2149-2151	of	abstract[104]|substance[108]	giv[104]|new[108]	_	_
16-24	2152-2155	the	abstract[104]|substance[108]|substance[110]	giv[104]|new[108]|giv[110]	_	_
16-25	2156-2161	aging	abstract[104]|substance[108]|abstract|substance[110]	giv[104]|new[108]|new|giv[110]	_	_
16-26	2162-2170	solution	abstract[104]|substance[108]|substance[110]	giv[104]|new[108]|giv[110]	_	_
16-27	2171-2172	.	_	_	_	_

#Text=It must be emphasized that the role of ethanol was simply to dissolve the drug and allow it to diffuse into the alcogel .
17-1	2173-2175	It	substance	giv	ana	17-18
17-2	2176-2180	must	_	_	_	_
17-3	2181-2183	be	_	_	_	_
17-4	2184-2194	emphasized	_	_	_	_
17-5	2195-2199	that	_	_	_	_
17-6	2200-2203	the	abstract[112]	new[112]	coref	20-6[133_112]
17-7	2204-2208	role	abstract[112]	new[112]	_	_
17-8	2209-2211	of	abstract[112]	new[112]	_	_
17-9	2212-2219	ethanol	abstract[112]|substance	new[112]|new	coref	23-17
17-10	2220-2223	was	_	_	_	_
17-11	2224-2230	simply	_	_	_	_
17-12	2231-2233	to	_	_	_	_
17-13	2234-2242	dissolve	_	_	_	_
17-14	2243-2246	the	substance[114]	giv[114]	coref	18-8[0_114]
17-15	2247-2251	drug	substance[114]	giv[114]	_	_
17-16	2252-2255	and	_	_	_	_
17-17	2256-2261	allow	_	_	_	_
17-18	2262-2264	it	substance	giv	_	_
17-19	2265-2267	to	_	_	_	_
17-20	2268-2275	diffuse	_	_	_	_
17-21	2276-2280	into	_	_	_	_
17-22	2281-2284	the	substance[116]	giv[116]	coref	21-25[147_116]
17-23	2285-2292	alcogel	substance[116]	giv[116]	_	_
17-24	2293-2294	.	_	_	_	_

#Text=Most research focuses only on the total drug loading content , but ignores the drug distribution and load mode in the carrier .
18-1	2295-2299	Most	abstract[117]	new[117]	_	_
18-2	2300-2308	research	abstract[117]	new[117]	_	_
18-3	2309-2316	focuses	_	_	_	_
18-4	2317-2321	only	_	_	_	_
18-5	2322-2324	on	_	_	_	_
18-6	2325-2328	the	abstract[120]	new[120]	_	_
18-7	2329-2334	total	abstract[120]	new[120]	_	_
18-8	2335-2339	drug	substance|abstract[120]	giv|new[120]	coref	18-15
18-9	2340-2347	loading	event|abstract[120]	giv|new[120]	coref	24-21
18-10	2348-2355	content	abstract[120]	new[120]	_	_
18-11	2356-2357	,	_	_	_	_
18-12	2358-2361	but	_	_	_	_
18-13	2362-2369	ignores	_	_	_	_
18-14	2370-2373	the	abstract[122]|abstract[123]	new[122]|new[123]	coref|coref	21-19[144_122]|21-19[145_123]
18-15	2374-2378	drug	substance|abstract[122]|abstract[123]	giv|new[122]|new[123]	coref	21-22[146_0]
18-16	2379-2391	distribution	abstract[122]|abstract[123]	new[122]|new[123]	_	_
18-17	2392-2395	and	abstract[123]	new[123]	_	_
18-18	2396-2400	load	abstract[123]|abstract|abstract[125]	new[123]|new|new[125]	coref	24-20[174_125]
18-19	2401-2405	mode	abstract[123]|abstract[125]	new[123]|new[125]	_	_
18-20	2406-2408	in	abstract[123]|abstract[125]	new[123]|new[125]	_	_
18-21	2409-2412	the	abstract[123]|abstract[125]|organization[126]	new[123]|new[125]|giv[126]	_	_
18-22	2413-2420	carrier	abstract[123]|abstract[125]|organization[126]	new[123]|new[125]|giv[126]	_	_
18-23	2421-2422	.	_	_	_	_

#Text=Moreover , drug-loading behaviors are commonly studied using adsorption isotherms and adsorption kinetic equations .
19-1	2423-2431	Moreover	_	_	_	_
19-2	2432-2433	,	_	_	_	_
19-3	2434-2446	drug-loading	abstract[127]	new[127]	_	_
19-4	2447-2456	behaviors	abstract[127]	new[127]	_	_
19-5	2457-2460	are	_	_	_	_
19-6	2461-2469	commonly	_	_	_	_
19-7	2470-2477	studied	_	_	_	_
19-8	2478-2483	using	_	_	_	_
19-9	2484-2494	adsorption	abstract|abstract[129]	new|new[129]	coref	19-12
19-10	2495-2504	isotherms	abstract[129]	new[129]	_	_
19-11	2505-2508	and	_	_	_	_
19-12	2509-2519	adsorption	abstract|abstract[131]	giv|new[131]	_	_
19-13	2520-2527	kinetic	abstract[131]	new[131]	_	_
19-14	2528-2537	equations	abstract[131]	new[131]	_	_
19-15	2538-2539	.	_	_	_	_

#Text=However , diffusion also play an important role in the drug-loading process , and we should consider both the effects of diffusion and adsorption/desorption .
20-1	2540-2547	However	_	_	_	_
20-2	2548-2549	,	_	_	_	_
20-3	2550-2559	diffusion	abstract	giv	coref	20-22
20-4	2560-2564	also	_	_	_	_
20-5	2565-2569	play	_	_	_	_
20-6	2570-2572	an	abstract[133]	giv[133]	_	_
20-7	2573-2582	important	abstract[133]	giv[133]	_	_
20-8	2583-2587	role	abstract[133]	giv[133]	_	_
20-9	2588-2590	in	abstract[133]	giv[133]	_	_
20-10	2591-2594	the	abstract[133]|abstract[135]	giv[133]|giv[135]	coref	23-19[164_135]
20-11	2595-2607	drug-loading	abstract[133]|substance|abstract[135]	giv[133]|new|giv[135]	coref	26-8
20-12	2608-2615	process	abstract[133]|abstract[135]	giv[133]|giv[135]	_	_
20-13	2616-2617	,	_	_	_	_
20-14	2618-2621	and	_	_	_	_
20-15	2622-2624	we	person	giv	ana	21-11
20-16	2625-2631	should	_	_	_	_
20-17	2632-2640	consider	_	_	_	_
20-18	2641-2645	both	abstract[137]	new[137]	_	_
20-19	2646-2649	the	abstract[137]	new[137]	_	_
20-20	2650-2657	effects	abstract[137]	new[137]	_	_
20-21	2658-2660	of	abstract[137]	new[137]	_	_
20-22	2661-2670	diffusion	abstract[137]|abstract	new[137]|giv	coref	21-31
20-23	2671-2674	and	abstract[137]	new[137]	_	_
20-24	2675-2696	adsorption/desorption	abstract[137]|abstract	new[137]|new	coref	21-33
20-25	2697-2698	.	_	_	_	_

#Text=So in this work , based on previous study , we have established a fundamental model to study the distribution of a drug in the alcogel and the interaction of diffusion and adsorption/desorption .
21-1	2699-2701	So	_	_	_	_
21-2	2702-2704	in	_	_	_	_
21-3	2705-2709	this	abstract[140]	giv[140]	_	_
21-4	2710-2714	work	abstract[140]	giv[140]	_	_
21-5	2715-2716	,	_	_	_	_
21-6	2717-2722	based	_	_	_	_
21-7	2723-2725	on	_	_	_	_
21-8	2726-2734	previous	abstract[141]	new[141]	_	_
21-9	2735-2740	study	abstract[141]	new[141]	_	_
21-10	2741-2742	,	_	_	_	_
21-11	2743-2745	we	person	giv	ana	23-3
21-12	2746-2750	have	_	_	_	_
21-13	2751-2762	established	_	_	_	_
21-14	2763-2764	a	abstract[143]	new[143]	_	_
21-15	2765-2776	fundamental	abstract[143]	new[143]	_	_
21-16	2777-2782	model	abstract[143]	new[143]	_	_
21-17	2783-2785	to	abstract[143]	new[143]	_	_
21-18	2786-2791	study	abstract[143]	new[143]	_	_
21-19	2792-2795	the	abstract[143]|abstract[144]|abstract[145]	new[143]|giv[144]|giv[145]	_	_
21-20	2796-2808	distribution	abstract[143]|abstract[144]|abstract[145]	new[143]|giv[144]|giv[145]	_	_
21-21	2809-2811	of	abstract[143]|abstract[144]|abstract[145]	new[143]|giv[144]|giv[145]	_	_
21-22	2812-2813	a	abstract[143]|abstract[144]|abstract[145]|substance[146]	new[143]|giv[144]|giv[145]|giv[146]	coref	24-24[175_146]
21-23	2814-2818	drug	abstract[143]|abstract[144]|abstract[145]|substance[146]	new[143]|giv[144]|giv[145]|giv[146]	_	_
21-24	2819-2821	in	abstract[143]|abstract[144]|abstract[145]|substance[146]	new[143]|giv[144]|giv[145]|giv[146]	_	_
21-25	2822-2825	the	abstract[143]|abstract[144]|abstract[145]|substance[146]|substance[147]	new[143]|giv[144]|giv[145]|giv[146]|giv[147]	_	_
21-26	2826-2833	alcogel	abstract[143]|abstract[144]|abstract[145]|substance[146]|substance[147]	new[143]|giv[144]|giv[145]|giv[146]|giv[147]	_	_
21-27	2834-2837	and	abstract[143]|abstract[145]	new[143]|giv[145]	_	_
21-28	2838-2841	the	abstract[143]|abstract[145]|abstract[148]	new[143]|giv[145]|new[148]	_	_
21-29	2842-2853	interaction	abstract[143]|abstract[145]|abstract[148]	new[143]|giv[145]|new[148]	_	_
21-30	2854-2856	of	abstract[143]|abstract[145]|abstract[148]	new[143]|giv[145]|new[148]	_	_
21-31	2857-2866	diffusion	abstract[143]|abstract[145]|abstract[148]|abstract	new[143]|giv[145]|new[148]|giv	coref	25-18
21-32	2867-2870	and	abstract[143]|abstract[145]|abstract[148]	new[143]|giv[145]|new[148]	_	_
21-33	2871-2892	adsorption/desorption	abstract[143]|abstract[145]|abstract[148]|abstract	new[143]|giv[145]|new[148]|giv	_	_
21-34	2893-2894	.	_	_	_	_

#Text=In this paper , RSV-loaded silica aerogel ( RLSA ) was prepared by freeze-drying .
22-1	2895-2897	In	_	_	_	_
22-2	2898-2902	this	abstract[151]	giv[151]	_	_
22-3	2903-2908	paper	abstract[151]	giv[151]	_	_
22-4	2909-2910	,	_	_	_	_
22-5	2911-2921	RSV-loaded	substance[153]	giv[153]	coref	24-12[170_153]
22-6	2922-2928	silica	substance|substance[153]	giv|giv[153]	coref	24-12
22-7	2929-2936	aerogel	substance[153]	giv[153]	_	_
22-8	2937-2938	(	_	_	_	_
22-9	2939-2943	RLSA	abstract	new	coref	24-15
22-10	2944-2945	)	_	_	_	_
22-11	2946-2949	was	_	_	_	_
22-12	2950-2958	prepared	_	_	_	_
22-13	2959-2961	by	_	_	_	_
22-14	2962-2975	freeze-drying	abstract	new	_	_
22-15	2976-2977	.	_	_	_	_

#Text=The reason we used freeze drying instead of supercritical drying is that the RSV will lose ethanol during the slow replacement process in supercritical drying .
23-1	2978-2981	The	abstract[156]	new[156]	_	_
23-2	2982-2988	reason	abstract[156]	new[156]	_	_
23-3	2989-2991	we	abstract[156]|person	new[156]|giv	ana	32-1
23-4	2992-2996	used	abstract[156]	new[156]	_	_
23-5	2997-3003	freeze	abstract[156]|abstract|event[159]	new[156]|new|new[159]	coref	30-11
23-6	3004-3010	drying	abstract[156]|event[159]	new[156]|new[159]	_	_
23-7	3011-3018	instead	abstract[156]	new[156]	_	_
23-8	3019-3021	of	abstract[156]	new[156]	_	_
23-9	3022-3035	supercritical	abstract[156]|event[160]	new[156]|new[160]	coref	23-24[165_160]
23-10	3036-3042	drying	abstract[156]|event[160]	new[156]|new[160]	_	_
23-11	3043-3045	is	_	_	_	_
23-12	3046-3050	that	_	_	_	_
23-13	3051-3054	the	abstract[161]	giv[161]	coref	36-4[0_161]
23-14	3055-3058	RSV	abstract[161]	giv[161]	_	_
23-15	3059-3063	will	_	_	_	_
23-16	3064-3068	lose	_	_	_	_
23-17	3069-3076	ethanol	substance	giv	coref	42-15
23-18	3077-3083	during	_	_	_	_
23-19	3084-3087	the	abstract[164]	giv[164]	_	_
23-20	3088-3092	slow	abstract[164]	giv[164]	_	_
23-21	3093-3104	replacement	event|abstract[164]	new|giv[164]	coref	43-12[277_0]
23-22	3105-3112	process	abstract[164]	giv[164]	_	_
23-23	3113-3115	in	abstract[164]	giv[164]	_	_
23-24	3116-3129	supercritical	abstract[164]|event[165]	giv[164]|giv[165]	coref	30-11[214_165]
23-25	3130-3136	drying	abstract[164]|event[165]	giv[164]|giv[165]	_	_
23-26	3137-3138	.	_	_	_	_

#Text=A series of characterizations were carried to compare the differences of silica aerogel and RLSA , and better understand the loading mode of the drug in silica aerogel .
24-1	3139-3140	A	abstract[166]	new[166]	_	_
24-2	3141-3147	series	abstract[166]	new[166]	_	_
24-3	3148-3150	of	abstract[166]	new[166]	_	_
24-4	3151-3168	characterizations	abstract[166]|abstract	new[166]|new	_	_
24-5	3169-3173	were	_	_	_	_
24-6	3174-3181	carried	_	_	_	_
24-7	3182-3184	to	_	_	_	_
24-8	3185-3192	compare	_	_	_	_
24-9	3193-3196	the	abstract[168]	new[168]	_	_
24-10	3197-3208	differences	abstract[168]	new[168]	_	_
24-11	3209-3211	of	abstract[168]	new[168]	_	_
24-12	3212-3218	silica	abstract[168]|substance|substance[170]|abstract[171]	new[168]|giv|giv[170]|giv[171]	coref|coref|coref	24-27|24-27[177_170]|30-6[211_171]
24-13	3219-3226	aerogel	abstract[168]|substance[170]|abstract[171]	new[168]|giv[170]|giv[171]	_	_
24-14	3227-3230	and	abstract[168]|abstract[171]	new[168]|giv[171]	_	_
24-15	3231-3235	RLSA	abstract[168]|abstract[171]|abstract	new[168]|giv[171]|giv	coref	28-14
24-16	3236-3237	,	_	_	_	_
24-17	3238-3241	and	_	_	_	_
24-18	3242-3248	better	_	_	_	_
24-19	3249-3259	understand	_	_	_	_
24-20	3260-3263	the	abstract[174]	giv[174]	_	_
24-21	3264-3271	loading	event|abstract[174]	giv|giv[174]	_	_
24-22	3272-3276	mode	abstract[174]	giv[174]	_	_
24-23	3277-3279	of	abstract[174]	giv[174]	_	_
24-24	3280-3283	the	abstract[174]|substance[175]	giv[174]|giv[175]	_	_
24-25	3284-3288	drug	abstract[174]|substance[175]	giv[174]|giv[175]	_	_
24-26	3289-3291	in	abstract[174]|substance[175]	giv[174]|giv[175]	_	_
24-27	3292-3298	silica	abstract[174]|substance[175]|substance|substance[177]	giv[174]|giv[175]|giv|giv[177]	coref|coref	28-5|28-5[201_177]
24-28	3299-3306	aerogel	abstract[174]|substance[175]|substance[177]	giv[174]|giv[175]|giv[177]	_	_
24-29	3307-3308	.	_	_	_	_

#Text=Furthermore , by establishing different boundary conditions and using Fick ’s second law to fit the apparent diffusion coefficient ( the apparent diffusion coefficients are all marked as “ diffusion coefficient ” in the manuscript hereafter for simplicity ) , three kinds of diffusion processes were studied .
25-1	3309-3320	Furthermore	_	_	_	_
25-2	3321-3322	,	_	_	_	_
25-3	3323-3325	by	_	_	_	_
25-4	3326-3338	establishing	_	_	_	_
25-5	3339-3348	different	abstract[179]	new[179]	_	_
25-6	3349-3357	boundary	place|abstract[179]	new|new[179]	_	_
25-7	3358-3368	conditions	abstract[179]	new[179]	_	_
25-8	3369-3372	and	_	_	_	_
25-9	3373-3378	using	_	_	_	_
25-10	3379-3383	Fick	person[180]|abstract[181]	new[180]|new[181]	_	_
25-11	3384-3386	’s	person[180]|abstract[181]	new[180]|new[181]	_	_
25-12	3387-3393	second	abstract[181]	new[181]	_	_
25-13	3394-3397	law	abstract[181]	new[181]	_	_
25-14	3398-3400	to	_	_	_	_
25-15	3401-3404	fit	_	_	_	_
25-16	3405-3408	the	abstract[183]	new[183]	coref	25-30[187_183]
25-17	3409-3417	apparent	abstract[183]	new[183]	_	_
25-18	3418-3427	diffusion	abstract|abstract[183]	giv|new[183]	coref	25-23
25-19	3428-3439	coefficient	abstract[183]	new[183]	_	_
25-20	3440-3441	(	_	_	_	_
25-21	3442-3445	the	abstract[185]	new[185]	_	_
25-22	3446-3454	apparent	abstract[185]	new[185]	_	_
25-23	3455-3464	diffusion	abstract|abstract[185]	giv|new[185]	coref	25-30
25-24	3465-3477	coefficients	abstract[185]	new[185]	_	_
25-25	3478-3481	are	_	_	_	_
25-26	3482-3485	all	_	_	_	_
25-27	3486-3492	marked	_	_	_	_
25-28	3493-3495	as	_	_	_	_
25-29	3496-3497	“	_	_	_	_
25-30	3498-3507	diffusion	abstract|abstract[187]	giv|giv[187]	coref	25-44
25-31	3508-3519	coefficient	abstract[187]	giv[187]	_	_
25-32	3520-3521	”	_	_	_	_
25-33	3522-3524	in	_	_	_	_
25-34	3525-3528	the	abstract[188]	new[188]	_	_
25-35	3529-3539	manuscript	abstract[188]	new[188]	_	_
25-36	3540-3549	hereafter	abstract[188]	new[188]	_	_
25-37	3550-3553	for	_	_	_	_
25-38	3554-3564	simplicity	abstract	new	ana	26-1
25-39	3565-3566	)	_	_	_	_
25-40	3567-3568	,	_	_	_	_
25-41	3569-3574	three	abstract[190]	new[190]	_	_
25-42	3575-3580	kinds	abstract[190]	new[190]	_	_
25-43	3581-3583	of	abstract[190]	new[190]	_	_
25-44	3584-3593	diffusion	abstract[190]|abstract|abstract[192]	new[190]|giv|new[192]	_	_
25-45	3594-3603	processes	abstract[190]|abstract[192]	new[190]|new[192]	_	_
25-46	3604-3608	were	_	_	_	_
25-47	3609-3616	studied	_	_	_	_
25-48	3617-3618	.	_	_	_	_

#Text=This facilitates the precise design of the drug-loading and -release system .
26-1	3619-3623	This	abstract	giv	_	_
26-2	3624-3635	facilitates	_	_	_	_
26-3	3636-3639	the	abstract[194]	new[194]	_	_
26-4	3640-3647	precise	abstract[194]	new[194]	_	_
26-5	3648-3654	design	abstract[194]	new[194]	_	_
26-6	3655-3657	of	abstract[194]	new[194]	_	_
26-7	3658-3661	the	abstract[194]|abstract[196]	new[194]|new[196]	_	_
26-8	3662-3674	drug-loading	abstract[194]|substance|abstract[196]	new[194]|giv|new[196]	_	_
26-9	3675-3678	and	abstract[194]|abstract[196]	new[194]|new[196]	_	_
26-10	3679-3687	-release	abstract[194]|abstract[196]	new[194]|new[196]	_	_
26-11	3688-3694	system	abstract[194]|abstract[196]	new[194]|new[196]	_	_
26-12	3695-3696	.	_	_	_	_

#Text=2. Results and Discussion
27-1	3697-3699	2.	_	_	_	_
27-2	3700-3707	Results	abstract	new	_	_
27-3	3708-3711	and	_	_	_	_
27-4	3712-3722	Discussion	abstract	new	_	_

#Text=2.1. The Characterization of Silica Aerogel and Trans-Resveratrol ( RSV)-Loaded Silica Aerogel ( RLSA )
28-1	3723-3727	2.1.	_	_	_	_
28-2	3728-3731	The	abstract[199]	new[199]	_	_
28-3	3732-3748	Characterization	abstract[199]	new[199]	_	_
28-4	3749-3751	of	abstract[199]	new[199]	_	_
28-5	3752-3758	Silica	abstract[199]|substance|substance[201]	new[199]|giv|giv[201]	coref|coref	28-11|28-8[204_201]
28-6	3759-3766	Aerogel	abstract[199]|substance[201]	new[199]|giv[201]	_	_
28-7	3767-3770	and	abstract[199]	new[199]	_	_
28-8	3771-3788	Trans-Resveratrol	abstract[199]|abstract|substance[204]	new[199]|giv|giv[204]	_	_
28-9	3789-3790	(	abstract[199]|substance[204]	new[199]|giv[204]	_	_
28-10	3791-3802	RSV)-Loaded	abstract[199]|substance[204]	new[199]|giv[204]	_	_
28-11	3803-3809	Silica	abstract[199]|substance|substance[204]	new[199]|giv|giv[204]	coref	30-6
28-12	3810-3817	Aerogel	abstract[199]|substance[204]	new[199]|giv[204]	_	_
28-13	3818-3819	(	_	_	_	_
28-14	3820-3824	RLSA	abstract	giv	coref	30-9
28-15	3825-3826	)	_	_	_	_

#Text=Figure 1
29-1	3827-3833	Figure	abstract[206]	new[206]	ana	30-1[0_206]
29-2	3834-3835	1	abstract[206]	new[206]	_	_

#Text=a shows the appearance of silica aerogel and RLSA after freeze drying .
30-1	3836-3837	a	abstract	giv	coref	37-1[255_0]
30-2	3838-3843	shows	_	_	_	_
30-3	3844-3847	the	abstract[208]	new[208]	_	_
30-4	3848-3858	appearance	abstract[208]	new[208]	_	_
30-5	3859-3861	of	abstract[208]	new[208]	_	_
30-6	3862-3868	silica	abstract[208]|substance|substance[210]|abstract[211]	new[208]|giv|new[210]|giv[211]	coref|coref	32-13|32-13[221_210]
30-7	3869-3876	aerogel	abstract[208]|substance[210]|abstract[211]	new[208]|new[210]|giv[211]	_	_
30-8	3877-3880	and	abstract[208]|abstract[211]	new[208]|giv[211]	_	_
30-9	3881-3885	RLSA	abstract[208]|abstract[211]|abstract	new[208]|giv[211]|giv	coref	32-8[219_0]
30-10	3886-3891	after	_	_	_	_
30-11	3892-3898	freeze	abstract|event[214]	giv|giv[214]	coref|coref	34-7[239_214]|44-2
30-12	3899-3905	drying	event[214]	giv[214]	_	_
30-13	3906-3907	.	_	_	_	_

#Text=The mass of both is 200 mg .
31-1	3908-3911	The	abstract[215]	new[215]	_	_
31-2	3912-3916	mass	abstract[215]	new[215]	_	_
31-3	3917-3919	of	abstract[215]	new[215]	_	_
31-4	3920-3924	both	abstract[215]	new[215]	_	_
31-5	3925-3927	is	_	_	_	_
31-6	3928-3931	200	substance[216]	new[216]	_	_
31-7	3932-3934	mg	substance[216]	new[216]	_	_
31-8	3935-3936	.	_	_	_	_

#Text=We can see that the volume of the RLSA is larger than silica aerogel , and the color becomes more opaque .
32-1	3937-3939	We	person	giv	_	_
32-2	3940-3943	can	_	_	_	_
32-3	3944-3947	see	_	_	_	_
32-4	3948-3952	that	_	_	_	_
32-5	3953-3956	the	abstract[218]	new[218]	_	_
32-6	3957-3963	volume	abstract[218]	new[218]	_	_
32-7	3964-3966	of	abstract[218]	new[218]	_	_
32-8	3967-3970	the	abstract[218]|abstract[219]	new[218]|giv[219]	_	_
32-9	3971-3975	RLSA	abstract[218]|abstract[219]	new[218]|giv[219]	_	_
32-10	3976-3978	is	_	_	_	_
32-11	3979-3985	larger	_	_	_	_
32-12	3986-3990	than	_	_	_	_
32-13	3991-3997	silica	substance|substance[221]	giv|giv[221]	coref|coref	33-10|33-10[228_221]
32-14	3998-4005	aerogel	substance[221]	giv[221]	_	_
32-15	4006-4007	,	_	_	_	_
32-16	4008-4011	and	_	_	_	_
32-17	4012-4015	the	abstract[222]	new[222]	_	_
32-18	4016-4021	color	abstract[222]	new[222]	_	_
32-19	4022-4029	becomes	_	_	_	_
32-20	4030-4034	more	_	_	_	_
32-21	4035-4041	opaque	_	_	_	_
32-22	4042-4043	.	_	_	_	_

#Text=A transmission electron microscope ( TEM ) image of silica aerogel shows that it is a dense structure formed by the accumulation of spherical particles , which is consistent with a scanning electron microscope ( SEM ) image .
33-1	4044-4045	A	abstract[226]	new[226]	coref	33-31[236_226]
33-2	4046-4058	transmission	substance[223]|object[224]|abstract[226]	new[223]|new[224]|new[226]	coref|coref	33-33[0_223]|33-32[234_224]
33-3	4059-4067	electron	substance[223]|object[224]|abstract[226]	new[223]|new[224]|new[226]	_	_
33-4	4068-4078	microscope	object[224]|abstract[226]	new[224]|new[226]	_	_
33-5	4079-4080	(	abstract[226]	new[226]	_	_
33-6	4081-4084	TEM	abstract|abstract[226]	new|new[226]	_	_
33-7	4085-4086	)	abstract[226]	new[226]	_	_
33-8	4087-4092	image	abstract[226]	new[226]	_	_
33-9	4093-4095	of	abstract[226]	new[226]	_	_
33-10	4096-4102	silica	abstract[226]|substance|substance[228]	new[226]|giv|giv[228]	ana|coref	33-14[0_228]|34-4
33-11	4103-4110	aerogel	abstract[226]|substance[228]	new[226]|giv[228]	_	_
33-12	4111-4116	shows	_	_	_	_
33-13	4117-4121	that	_	_	_	_
33-14	4122-4124	it	substance	giv	coref	33-16[230_0]
33-15	4125-4127	is	_	_	_	_
33-16	4128-4129	a	substance[230]	giv[230]	coref	34-3[238_230]
33-17	4130-4135	dense	substance[230]	giv[230]	_	_
33-18	4136-4145	structure	substance[230]	giv[230]	_	_
33-19	4146-4152	formed	substance[230]	giv[230]	_	_
33-20	4153-4155	by	substance[230]	giv[230]	_	_
33-21	4156-4159	the	substance[230]|abstract[231]	giv[230]|new[231]	_	_
33-22	4160-4172	accumulation	substance[230]|abstract[231]	giv[230]|new[231]	_	_
33-23	4173-4175	of	substance[230]|abstract[231]	giv[230]|new[231]	_	_
33-24	4176-4185	spherical	substance[230]|abstract[231]|object[232]	giv[230]|new[231]|new[232]	_	_
33-25	4186-4195	particles	substance[230]|abstract[231]|object[232]	giv[230]|new[231]|new[232]	_	_
33-26	4196-4197	,	substance[230]	giv[230]	_	_
33-27	4198-4203	which	substance[230]	giv[230]	_	_
33-28	4204-4206	is	substance[230]	giv[230]	_	_
33-29	4207-4217	consistent	substance[230]	giv[230]	_	_
33-30	4218-4222	with	substance[230]	giv[230]	_	_
33-31	4223-4224	a	substance[230]|abstract[236]	giv[230]|giv[236]	_	_
33-32	4225-4233	scanning	substance[230]|object[234]|abstract[236]	giv[230]|giv[234]|giv[236]	_	_
33-33	4234-4242	electron	substance[230]|substance|object[234]|abstract[236]	giv[230]|giv|giv[234]|giv[236]	_	_
33-34	4243-4253	microscope	substance[230]|object[234]|abstract[236]	giv[230]|giv[234]|giv[236]	_	_
33-35	4254-4255	(	substance[230]|abstract[236]	giv[230]|giv[236]	_	_
33-36	4256-4259	SEM	substance[230]|abstract|abstract[236]	giv[230]|new|giv[236]	_	_
33-37	4260-4261	)	substance[230]|abstract[236]	giv[230]|giv[236]	_	_
33-38	4262-4267	image	substance[230]|abstract[236]	giv[230]|giv[236]	_	_
33-39	4268-4269	.	_	_	_	_

#Text=Compared with the silica aerogel after supercritical drying , its skeleton structure is denser and the density is larger .
34-1	4270-4278	Compared	_	_	_	_
34-2	4279-4283	with	_	_	_	_
34-3	4284-4287	the	substance[238]	giv[238]	ana	34-10[0_238]
34-4	4288-4294	silica	substance|substance[238]	giv|giv[238]	coref	41-19
34-5	4295-4302	aerogel	substance[238]	giv[238]	_	_
34-6	4303-4308	after	substance[238]	giv[238]	_	_
34-7	4309-4322	supercritical	substance[238]|event[239]	giv[238]|giv[239]	coref	44-2[279_239]
34-8	4323-4329	drying	substance[238]|event[239]	giv[238]|giv[239]	_	_
34-9	4330-4331	,	_	_	_	_
34-10	4332-4335	its	substance|substance[242]	giv|giv[242]	coref	34-10[242_0]
34-11	4336-4344	skeleton	person|substance[242]	new|giv[242]	coref	41-17[264_0]
34-12	4345-4354	structure	substance[242]	giv[242]	_	_
34-13	4355-4357	is	_	_	_	_
34-14	4358-4364	denser	_	_	_	_
34-15	4365-4368	and	_	_	_	_
34-16	4369-4372	the	abstract[243]	new[243]	_	_
34-17	4373-4380	density	abstract[243]	new[243]	_	_
34-18	4381-4383	is	_	_	_	_
34-19	4384-4390	larger	_	_	_	_
34-20	4391-4392	.	_	_	_	_

#Text=However , the pore size is smaller and most of it consists of micropores .
35-1	4393-4400	However	_	_	_	_
35-2	4401-4402	,	_	_	_	_
35-3	4403-4406	the	abstract[245]	giv[245]	ana	35-11[0_245]
35-4	4407-4411	pore	abstract|abstract[245]	new|giv[245]	coref	42-22[270_0]
35-5	4412-4416	size	abstract[245]	giv[245]	_	_
35-6	4417-4419	is	_	_	_	_
35-7	4420-4427	smaller	_	_	_	_
35-8	4428-4431	and	_	_	_	_
35-9	4432-4436	most	_	_	_	_
35-10	4437-4439	of	_	_	_	_
35-11	4440-4442	it	abstract	giv	coref	36-11[252_0]
35-12	4443-4451	consists	_	_	_	_
35-13	4452-4454	of	_	_	_	_
35-14	4455-4465	micropores	person	new	_	_
35-15	4466-4467	.	_	_	_	_

#Text=The structure of RSV has a long rod shape with the size on the order of micrometers shown in
36-1	4468-4471	The	abstract[248]	new[248]	_	_
36-2	4472-4481	structure	abstract[248]	new[248]	_	_
36-3	4482-4484	of	abstract[248]	new[248]	_	_
36-4	4485-4488	RSV	abstract[248]|abstract	new[248]|giv	coref	41-5[258_0]
36-5	4489-4492	has	_	_	_	_
36-6	4493-4494	a	abstract[251]	new[251]	coref	41-9[261_251]
36-7	4495-4499	long	abstract[251]	new[251]	_	_
36-8	4500-4503	rod	object|abstract[251]	new|new[251]	coref	41-12
36-9	4504-4509	shape	abstract[251]	new[251]	_	_
36-10	4510-4514	with	abstract[251]	new[251]	_	_
36-11	4515-4518	the	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
36-12	4519-4523	size	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
36-13	4524-4526	on	abstract[251]|abstract[252]	new[251]|giv[252]	_	_
36-14	4527-4530	the	abstract[251]|abstract[252]|abstract[253]	new[251]|giv[252]|new[253]	_	_
36-15	4531-4536	order	abstract[251]|abstract[252]|abstract[253]	new[251]|giv[252]|new[253]	_	_
36-16	4537-4539	of	abstract[251]|abstract[252]|abstract[253]	new[251]|giv[252]|new[253]	_	_
36-17	4540-4551	micrometers	abstract[251]|abstract[252]|abstract[253]|abstract[254]	new[251]|giv[252]|new[253]|new[254]	_	_
36-18	4552-4557	shown	abstract[251]|abstract[252]|abstract[253]|abstract[254]	new[251]|giv[252]|new[253]|new[254]	_	_
36-19	4558-4560	in	abstract[251]|abstract[252]|abstract[253]|abstract[254]	new[251]|giv[252]|new[253]|new[254]	_	_

#Text=Figure 1
37-1	4561-4567	Figure	abstract[255]	giv[255]	ana	39-1[0_255]
37-2	4568-4569	1	abstract[255]	giv[255]	_	_

#Text=e.
38-1	4570-4572	e.	_	_	_	_

#Text=It can be seen from
39-1	4573-4575	It	abstract	giv	coref	40-1[257_0]
39-2	4576-4579	can	_	_	_	_
39-3	4580-4582	be	_	_	_	_
39-4	4583-4587	seen	_	_	_	_
39-5	4588-4592	from	_	_	_	_

#Text=Figure 1
40-1	4593-4599	Figure	abstract[257]	giv[257]	_	_
40-2	4600-4601	1	abstract[257]	giv[257]	_	_

#Text=c , f that the recrystallized RSV with a micron-sized long rod shape is integrated with the dense silica network skeleton .
41-1	4602-4603	c	_	_	_	_
41-2	4604-4605	,	_	_	_	_
41-3	4606-4607	f	_	_	_	_
41-4	4608-4612	that	_	_	_	_
41-5	4613-4616	the	abstract[258]	giv[258]	coref	42-7[266_258]
41-6	4617-4631	recrystallized	abstract[258]	giv[258]	_	_
41-7	4632-4635	RSV	abstract[258]	giv[258]	_	_
41-8	4636-4640	with	abstract[258]	giv[258]	_	_
41-9	4641-4642	a	abstract[258]|abstract[261]	giv[258]|giv[261]	ana	42-1[0_261]
41-10	4643-4655	micron-sized	abstract[258]|abstract|abstract[261]	giv[258]|new|giv[261]	_	_
41-11	4656-4660	long	abstract[258]|abstract[261]	giv[258]|giv[261]	_	_
41-12	4661-4664	rod	abstract[258]|object|abstract[261]	giv[258]|giv|giv[261]	_	_
41-13	4665-4670	shape	abstract[258]|abstract[261]	giv[258]|giv[261]	_	_
41-14	4671-4673	is	_	_	_	_
41-15	4674-4684	integrated	_	_	_	_
41-16	4685-4689	with	_	_	_	_
41-17	4690-4693	the	person[264]	giv[264]	_	_
41-18	4694-4699	dense	person[264]	giv[264]	_	_
41-19	4700-4706	silica	substance|place[263]|person[264]	giv|new[263]|giv[264]	coref	42-25
41-20	4707-4714	network	place[263]|person[264]	new[263]|giv[264]	_	_
41-21	4715-4723	skeleton	person[264]	giv[264]	_	_
41-22	4724-4725	.	_	_	_	_

#Text=This is may be due to the RSV dissolving into small molecules in an ethanol solution , which can diffuse into the pores of silica alcogel .
42-1	4726-4730	This	abstract	giv	_	_
42-2	4731-4733	is	_	_	_	_
42-3	4734-4737	may	_	_	_	_
42-4	4738-4740	be	_	_	_	_
42-5	4741-4744	due	_	_	_	_
42-6	4745-4747	to	_	_	_	_
42-7	4748-4751	the	abstract[266]	giv[266]	coref	43-3[0_266]
42-8	4752-4755	RSV	abstract[266]	giv[266]	_	_
42-9	4756-4766	dissolving	_	_	_	_
42-10	4767-4771	into	_	_	_	_
42-11	4772-4777	small	plant[267]	new[267]	_	_
42-12	4778-4787	molecules	plant[267]	new[267]	_	_
42-13	4788-4790	in	_	_	_	_
42-14	4791-4793	an	substance[269]	new[269]	_	_
42-15	4794-4801	ethanol	substance|substance[269]	giv|new[269]	_	_
42-16	4802-4810	solution	substance[269]	new[269]	_	_
42-17	4811-4812	,	substance[269]	new[269]	_	_
42-18	4813-4818	which	substance[269]	new[269]	_	_
42-19	4819-4822	can	substance[269]	new[269]	_	_
42-20	4823-4830	diffuse	substance[269]	new[269]	_	_
42-21	4831-4835	into	substance[269]	new[269]	_	_
42-22	4836-4839	the	substance[269]|abstract[270]	new[269]|giv[270]	_	_
42-23	4840-4845	pores	substance[269]|abstract[270]	new[269]|giv[270]	_	_
42-24	4846-4848	of	substance[269]|abstract[270]	new[269]|giv[270]	_	_
42-25	4849-4855	silica	substance[269]|abstract[270]|substance|substance[272]	new[269]|giv[270]|giv|new[272]	_	_
42-26	4856-4863	alcogel	substance[269]|abstract[270]|substance[272]	new[269]|giv[270]|new[272]	_	_
42-27	4864-4865	.	_	_	_	_

#Text=However , RSV precipitates due to minimal solubility in water during solvent replacement .
43-1	4866-4873	However	_	_	_	_
43-2	4874-4875	,	_	_	_	_
43-3	4876-4879	RSV	abstract	giv	coref	44-9[281_0]
43-4	4880-4892	precipitates	_	_	_	_
43-5	4893-4896	due	_	_	_	_
43-6	4897-4899	to	_	_	_	_
43-7	4900-4907	minimal	substance[274]	new[274]	_	_
43-8	4908-4918	solubility	substance[274]	new[274]	_	_
43-9	4919-4921	in	substance[274]	new[274]	_	_
43-10	4922-4927	water	substance[274]|substance	new[274]|new	_	_
43-11	4928-4934	during	_	_	_	_
43-12	4935-4942	solvent	substance|event[277]	new|giv[277]	coref	44-5[280_0]
43-13	4943-4954	replacement	event[277]	giv[277]	_	_
43-14	4955-4956	.	_	_	_	_

#Text=After freeze drying , the solvent evaporates and the RSV recrystallizes .
44-1	4957-4962	After	_	_	_	_
44-2	4963-4969	freeze	abstract|event[279]	giv|giv[279]	_	_
44-3	4970-4976	drying	event[279]	giv[279]	_	_
44-4	4977-4978	,	_	_	_	_
44-5	4979-4982	the	substance[280]	giv[280]	_	_
44-6	4983-4990	solvent	substance[280]	giv[280]	_	_
44-7	4991-5001	evaporates	_	_	_	_
44-8	5002-5005	and	_	_	_	_
44-9	5006-5009	the	abstract[281]	giv[281]	_	_
44-10	5010-5013	RSV	abstract[281]	giv[281]	_	_
44-11	5014-5028	recrystallizes	_	_	_	_
44-12	5029-5030	.	_	_	_	_
